Praxis Precision Medicines/$PRAX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Praxis Precision Medicines
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Ticker
$PRAX
Sector
Primary listing
Employees
168
Headquarters
Website
PRAX Metrics
BasicAdvanced
$8.6B
-
-$13.48
2.90
-
Price and volume
Market cap
$8.6B
Beta
2.9
52-week high
$356.00
52-week low
$26.70
Average daily volume
452K
Financial strength
Current ratio
10.221
Quick ratio
10.027
Total debt to equity
0.013
Profitability
EBITDA (TTM)
-326.058
Management effectiveness
Return on assets (TTM)
-28.69%
Return on equity (TTM)
-45.83%
Valuation
Price to book
8.89
Price to tangible book (TTM)
8.89
Price to free cash flow (TTM)
-27.996
Free cash flow yield (TTM)
-3.57%
Free cash flow per share (TTM)
-11.07
Growth
Earnings per share change (TTM)
31.99%
3-year earnings per share growth (CAGR)
-42.16%
What the Analysts think about PRAX
Analyst ratings (Buy, Hold, Sell) for Praxis Precision Medicines stock.
PRAX Financial Performance
Revenues and expenses
PRAX Earnings Performance
Company profitability
PRAX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Praxis Precision Medicines stock?
Praxis Precision Medicines (PRAX) has a market cap of $8.6B as of March 11, 2026.
What is the P/E ratio for Praxis Precision Medicines stock?
The price to earnings (P/E) ratio for Praxis Precision Medicines (PRAX) stock is 0 as of March 11, 2026.
Does Praxis Precision Medicines stock pay dividends?
No, Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders as of March 11, 2026.
When is the next Praxis Precision Medicines dividend payment date?
Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Praxis Precision Medicines?
Praxis Precision Medicines (PRAX) has a beta rating of 2.9. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.